Davenport & Co’s Bioventus BVS Stock Holding History

Davenport & Co’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14,700	Closed	-$38K	–	1047
2022 Q4	$38K	Sell	14,700 -1	-0%	-$4	﹤0.01%	994
2022 Q3	$103K	Hold	14,701	–	–	﹤0.01%	961
2022 Q2	$100K	Sell	14,701 -21,978	-60%	-$224K	﹤0.01%	965
2022 Q1	$517K	Buy	36,679 +21,978	+150%	+$294K	﹤0.01%	726
2021 Q4	$213K	Buy	+14,701	New	+$209K	﹤0.01%	1010

Other funds holding BVS

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

JIC

Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

KLC

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Davenport & Co's BVS Position: Q1 2023 in Review

Davenport & Co sold out of Bioventus (BVS) in Q1 2023, closing a stake of 14,700 shares — an estimated $38K sold.

Davenport & Co first reported a position in BVS in Q4 2021 and held it in 5 quarters. The position peaked at $517K in Q1 2022. 71 funds tracked by Wall St. Rank hold BVS as of Q1 2023.

Davenport & Co reported no remaining Bioventus position as of Q1 2023 after selling out during the quarter.
Davenport & Co sold 14,700 Bioventus shares in Q1 2023, an estimated $38K.
Davenport & Co first reported a position in Bioventus in Q4 2021 and held it in 5 quarters.
Davenport & Co's Bioventus position peaked at $517K in Q1 2022.
71 funds tracked by Wall St. Rank held Bioventus as of Q1 2023.

Based on Davenport & Co's 13F filing for Q1 2023, filed 27 Apr 2023.